Skip to main content
Cancel

Beyond Discovery: Where Capital is Flowing in Clinical AI

July 29, 2026

Beyond Discovery: Where Capital is Flowing in Clinical AI

By Tyler Morris, Director, Funding & Partnering, Biocom

For the past several years, AI investment in life sciences has centered on discovery: models that generate drug candidates, predict protein structures and compress years of medicinal chemistry into weeks. That story is far from over, but it is no longer the whole story. As AI-generated pipelines expand, a new bottleneck is emerging further downstream: the clinical trial itself. Increasingly, investors are asking not just which company can find the next molecule, but which company can help sponsors run the trial that proves it works.

That shift is starting to show up in the data and in the questions investors are asking before they write a check.

The Capital is Moving Downstream

PitchBook’s AI in Drug Development analyst note tracks a widening set of applications for AI in clinical development, including patient selection, biomarker identification, trial design, recruitment, and proposal writing. Its Q1 2026 Pharma Biotools VC Trends report goes further, noting that early-stage funding for AI-native pharma-biotools companies surpassed non-AI-native investment in 2025 for the first time.

Discovery platforms still capture the largest rounds. But as more AI-generated candidates enter the pipeline, the constraint on getting a therapy to market is shifting from finding a candidate to proving one, and capital is beginning to follow that logic into clinical infrastructure.

PitchBook’s trailing-12-month VC trends data through March 31, 2026, helps define where that money is concentrating. Digital R&D and clinical infrastructure attracted $400.1 million across 57 deals. Within that segment, clinical operations and data-capture companies accounted for $245.9 million across 10 deals, compared with $52.2 million for biological modeling and simulation and $39.8 million for regulatory and safety analytics. This is not a wholesale rotation away from discovery. It is a targeted build-out around the bottlenecks closest to enrollment, evidence generation and compliance. The most investable categories tend to have both a clear sponsor budget owner and measurable time-to-value: patient matching and recruitment, digital twins and model-informed controls, and decentralized monitoring infrastructure. Generative-AI copilots are emerging as an additional operational layer, but remain earlier in their validation and governance maturity.

Smarter Patient Matching and Recruitment

Conventional screening requires teams to compare lengthy eligibility criteria against fragmented medical histories, slow work that can miss qualified participants. The NIH-developed TrialGPT illustrates the upside: in a Nature Communcations study spanning 183 synthetic patients and more than 75,000 trial annotations, the system recalled over 90% of relevant studies while searching less than 6% of the initial collection, cutting screening time by 42.6%. Recruitment tools like this are attractive to investors because the ROI case is easy to articulate: faster enrollment has a direct, measurable effect on trial cost and timeline.

Adaptive Design and Digital Twins

Predictive models that simulate recruitment feasibility, identify response-linked biomarkers, and generate digital twins—statistical representations of how a patient might progress under standard care—are drawing commercial interest because they promise to reduce control-arm requirements and improve statistical power, particularly in rare diseases where recruitment is difficult.

Continuous Monitoring Infrastructure

Wearables, sensors and connected applications are producing richer, more continuous participant data between visits. AI models that convert those streams into digital biomarkers and safety signals support decentralized and hybrid trial designs, a structural shift that itself requires new infrastructure to fund.

Generative AI as an Operational Layer

Protocol drafting, site communications, medical coding and clinical-study-report preparation are emerging use cases, though this category is earlier-stage and carries more execution risk given the accountability requirements around generated content.

Why Clinical Infrastructure is the Next Opportunity

The logic is straightforward: an expanding pipeline of AI-generated candidates does nothing for patients if the clinical development engine underneath it cannot keep pace. Discovery platforms have compressed the front end of drug development; clinical infrastructure companies are now positioned to compress, or de-risk, the back end, which is where most of the time, cost and failure risk in drug development actually lives. Investors who have already backed discovery are, in effect, incentivized to also back the infrastructure that lets those discoveries reach a clinical readout.

What Investors Examine in Diligence

As capital moves into this category, diligence is tightening around a few consistent questions:

  • Validation. Has the tool been prospectively validated in real clinical workflows, or only demonstrated retrospectively on synthetic or historical data? TrialGPT’s authors are explicit that prospective validation remains an open step, a distinction investors are learning to probe for.
  • Data access. Does the company have durable, compliant access to the clinical and real-world data its models depend on, or is it reliant on data-sharing relationships that could change?
  • Regulatory credibility. The FDA has reported experience with more than 500 drug and biological-product submissions containing AI components since 2016, and its 2025 draft guidance proposes a risk-based framework tying model credibility to a defined context of use. Companies that can speak fluently to this framework—documentation, validation, monitoring and lifecycle maintenance—read as more investable than those treating AI as a black box.
  • Integration into sponsor workflows. A model that performs well in isolation but requires sponsors to rebuild their processes around it faces a much harder commercial path than one designed to sit inside existing clinical, statistical and regulatory workflows.

Sponsors and reviewers are also increasingly expecting AI-involved protocols and reports to follow established transparency standards such as SPIRIT-AI and CONSORT-AI, another signal investors are learning to check for during diligence.

The Partnerships this Category Requires

No single go-to-market channel is sufficient for most clinical-AI infrastructure companies. Selling directly to a sponsor establishes the economic buyer and creates a path to portfolio-level value, but it can also trap a startup in bespoke pilots. CRO partnerships can turn a point solution into a repeatable deployment across studies, therapeutic areas and geographies. Health systems and site networks provide the clinical data access, workflow integration and prospective-validation environment needed to prove that a product works in practice. Cloud, data-infrastructure and EHR vendors supply the governed technical foundation required to scale securely.

Recent partnerships show this stack forming in the market. Bayer and Henry Ford Health announced a 2026 collaboration using AI, analytics and EHR data to improve trial design and patient identification. ICON’s partnership with Microsoft is designed to scale a secure, governed AI platform across protocol design, feasibility, site identification, monitoring, data review and regulatory documentation. These arrangements suggest a practical commercialization sequence for founders: secure an anchor partner to generate evidence, a distribution or operating partner to repeat the deployment and an infrastructure partner to make security and interoperability credible.

The details determine whether such partnerships become platforms or remain pilots. Data rights, validation responsibilities, model-change approval, integration ownership and commercial terms should be explicit at the outset. Partnerships tend to stall when every deployment requires custom engineering, access to essential data ends with the project or accountability for an AI-assisted decision is unclear. The strongest arrangements create a reusable integration pattern and a jointly owned evidence roadmap.

What Founders Need to Show to Move from Pilot to Platform

Moving from a promising pilot to a platform that can support a Series B and beyond requires more than another accuracy benchmark. Founders need to demonstrate four forms of readiness:

  • Reproducible evidence. The company can repeat its result prospectively across sites, populations and workflows, using predefined success measures tied to enrollment speed, data quality, cost or decision accuracy.
  • Lifecycle governance. Model versions, training-data provenance, validation results, bias testing, human oversight, change control and ongoing performance monitoring are documented and auditable. The FDA’s context-of-use framework should be reflected in the product’s operating model, not treated as language added for a regulatory meeting.
  • Workflow and technical integration. The product connects to EHR, CTMS, EDC and sponsor data environments through standardized interfaces; role-based access, security and escalation paths are built in; and users can adopt the tool without rebuilding the trial process around it.
  • Repeatable economics. Implementation time and customization decline as deployments grow, pricing maps to measurable customer value, and renewals or study-to-study expansion show that the product is becoming infrastructure rather than an experiment.

What founders most often get wrong is scaling the model before scaling the operating system around it. A technically impressive tool can still fail diligence if every customer needs a different implementation, if the evidence base does not travel beyond the first site or if no one owns model performance after launch. The companies most likely to earn growth-stage backing will show that clinical evidence, governance, integration and unit economics improve together as the platform expands.

References